← USPTO Patent Grants

Anti-claudin 18.2 and anti-4-1BB bispecific antibodies and uses thereof

Grant US12577313B2 Kind: B2 Mar 17, 2026

Assignee

I-Mab Biopharma US Limited

Inventors

Wenqing Jiang, Lei Fang, Zhengyi Wang, Bingshi Guo, Eunyoung Park, Eunsil Sung, Byungje Sung

Abstract

Provided are bispecific and multi-specific antibodies that target both claudin 18.2 (CLDN18.2) and 4-1BB. These antibodies, in the absence of CLDN18.2-expressing cells, can bind to 4-1BB but are unable to activate 4-1BB signaling. In the presence of CLDN18.2-expressing cells, however, these antibodies can trigger CLDN18.2-dependent 4-1BB signaling, leading to potent immune response to the CLDN18.2-expressing tumor cells.

CPC Classifications

C07K 16/2878 C07K 16/28 C07K 2317/31 C07K 2317/52 C07K 2317/622 C07K 2317/92 C07K 2317/41 C07K 2317/55 C07K 2317/64 C07K 2317/71 C07K 2317/75 C07K 2317/56 C07K 2317/565 A61P 35/00 A61K 2039/505

Filing Date

2022-03-01

Application No.

17683869

Claims

15